Sales force interactions with healthcare professionals are among the highest-risk commercial activities in the life sciences industry. These engagements sit at the intersection of commercial strategy, clinical decision-making, and strict regulatory expectations, leaving little margin for error.
This article builds on the first in our blog series, "Why AI Alone Isn’t Enough in Life Sciences Investigations," which explains why human expertise must remain central to AI-enabled compliance programs. Here, we focus on how in-house commercial compliance professionals can apply AI to strengthen oversight of sales force activity – without sacrificing regulatory judgment.
Why Human Expertise Remains Central
AI can meaningfully enhance the speed, scale, and consistency of commercial monitoring, but it does not replace the expertise required to interpret regulatory nuance. Experienced compliance professionals provide context, assess intent, make escalation decisions, engage with pharmacovigilance and privacy stakeholders, and continuously refine monitoring frameworks as regulations evolve. The strongest compliance programs intentionally combine AI-driven detection with expert review and decision-making.
This is true across fields and industries: compliance monitoring is a complex and nuanced exercise, and domain expertise, such as in the life sciences and pharmaceutical industry, on human teams is an essential layer to retain – even when technology is used to accelerate their efforts.
Monitoring Sales Force Interactions
Life sciences companies monitor a broad range of sales force activities, including spend and meal limits, visit frequency, sampling practices, off-label discussion risk, interactions with excluded specialties, and adherence to approved promotional content.
Among these, sales call notes represent a particularly rich – and complex – source of compliance insight. Call notes often capture how products are positioned in the field, the questions raised by healthcare professionals (“HCP”), and feedback on real-world use. At the same time, they may contain early indicators of potential compliance risk that warrant further review.
Using Relativity aiR for Review, compliance teams can rapidly surface patterns related to high-risk promotional behavior across large volumes of call notes. This enables organizations to move away from purely retrospective reviews and toward more proactive, risk-based oversight – shortening feedback cycles and supporting timely corrective action.
Illustrative Compliance Risk Areas: Adverse Events
Adverse Events (AEs) are widely recognized as one of the most significant compliance risks associated with sales force interactions in the pharmaceutical and biotech sectors. An AE is defined as any untoward medical occurrence experienced by a patient or clinical trial participant, regardless of whether it is considered product related. Failure to properly identify and escalate potential AEs can constitute a serious breach of pharmacovigilance obligations and applicable healthcare regulations.
During sales calls, HCP may share patient experiences that meet AE reporting criteria without expressly labeling them as such. These discussions may involve unexpected side effects, treatment discontinuation, lack of efficacy accompanied by adverse outcomes, or new diagnoses following product use. Distinguishing between reportable AEs and non-reportable hypothetical or general clinical discussions requires careful review and regulatory judgment.
Surface Compliance Risks Faster
While there are serious implications on the line, fit-for-purpose AI tools can help life sciences organizations stay on top of compliance and expedite and escalate their findings proactively. Using generative-AI-powered aiR for Review, teams can surface call notes that reference potential AEs, including – illustratively but not exhaustively – mentions of:
- Side effects observed in patients, whether consistent with or exceeding approved labeling
- Negative patient reactions such as nausea, vomiting, severe headaches, fever, or hospitalization
- Unfavorable or unintended signs noted by an HCP, including abnormal laboratory findings
- Negative responses related to dosing or administration
- Statements questioning product quality or tolerability
Examples drawn from sales call notes may include comments such as:
- "Two patients discontinued therapy due to severe headaches, although I continue to prescribe given the results."
- "The patient developed significant nausea and vomiting after two months of treatment."
- "Side effects observed in practice appear more pronounced than those described in clinical trial data.”
These examples are illustrative rather than exhaustive and are intended to support timely escalation to pharmacovigilance teams while also enabling compliance professionals to identify broader trends, assess training needs, and refine sales force guidance
Illustrative Compliance Risk Areas: Inappropriate Handling of Patient or HCP Information
Inappropriate handling of patient or HCP information represents another critical compliance risk area for commercial organizations. Sales representatives may inadvertently document information they are not authorized to collect, including personally identifiable information (PII) or protected health information (PHI), during routine interactions with HCPs.
Improper collection, recording, or transmission of such data can expose companies to significant privacy, data protection, and regulatory risk. With aiR for Review for Review, compliance teams can flag call notes that may reference identifiable patient details combined with health, treatment, or dosing information. These examples are illustrative and support structured human review, remediation, and ongoing sales force training.
In addition to monitoring sales call notes, compliance teams can implement Relativity’s AI‑powered PII detection capabilities in concert with commercial compliance workflows. When used alongside AI-driven review of sales force notes, these tools help identify and classify sensitive personal data across broader data sets, supporting more consistent detection of PII and PHI and enabling faster, more targeted response. Together, these capabilities allow organizations to take a more holistic approach to identifying privacy risk – linking insights from sales interactions with enterprise-wide data protection and compliance efforts.
AI materially improves the speed, consistency, and effectiveness of compliance monitoring with applicable data protection laws and industry standards governing personally identifiable information and protected health information. It supports the implementation of appropriate safeguards to protect patient privacy and helps sustain trust with HCPs.
Conclusion
AI enables compliance teams to review more sales force activity, more consistently, and at greater speed, but it is most effective when paired with experienced professionals who understand commercial realities and regulatory expectations. For life sciences organizations, AI serves as a force multiplier—supporting earlier risk detection, stronger governance, and more effective engagement with the sales organization.
Learn more about how Relativity aiR supports life sciences commercial compliance monitoring.
Graphics for this article were created by Kael Rose.
